This post was published on ZYX Buy Change Alert.
BLCM is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. It is an upcoming IPO
This is a call to buy in the IPO at the IPO price. To be clear, this is not a call to buy the stock post IPO or in the open market when the stock starts trading.
Consider contacting your broker and requesting up to 100% of the full core position size. Consider buying only if the IPO is priced under $20.50, preferably under $19.50.
Hard stops are mandatory in the zone of $0.01 below the offering price to $0.13 below the offering price. It is best to stagger the stops. Targets later.
If you are not able to get in the IPO, we will evaluate after it starts trading to see if it is still a buy.
You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.